
Infex’s resistance bypass drug program ready for clinic
Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through… Read More








